Published in Oncotarget on August 10, 2016
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA (2015) 5.45
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol (2012) 5.16
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn (2015) 3.84
The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood (2016) 3.21
Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc (2008) 2.80
Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology (2006) 2.50
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics (2008) 2.35
Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol (2009) 2.14
Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction. Arch Pathol Lab Med (2014) 2.02
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol (2013) 1.99
Identification of errors introduced during high throughput sequencing of the T cell receptor repertoire. BMC Genomics (2011) 1.87
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood (2003) 1.87
Bayesian approach to transforming public gene expression repositories into disease diagnosis databases. Proc Natl Acad Sci U S A (2010) 1.84
Next-generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med (2015) 1.81
INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol (2011) 1.78
Can digital pathology result in cost savings? A financial projection for digital pathology implementation at a large integrated health care organization. J Pathol Inform (2014) 1.76
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol (2014) 1.70
Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine? Clin Radiol (2015) 1.61
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res (2014) 1.57
Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics (2014) 1.53
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J (2009) 1.46
Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol (2013) 1.41
Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Semin Cancer Biol (2014) 1.40
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol (2013) 1.33
Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care. Clin Genet (2015) 1.32
Biomarkers for personalized oncology: recent advances and future challenges. Metabolism (2014) 1.29
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol (2014) 1.28
A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases. Genome Med (2015) 1.26
Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. JAMA Oncol (2016) 1.19
The diversity of soft tissue tumours with EWSR1 gene rearrangements: a review. Histopathology (2013) 1.17
Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev (2014) 1.16
Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. J Clin Oncol (2015) 1.16
Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci (2005) 1.13
Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs (2012) 1.05
Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Med (2014) 1.04
Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin Cancer Res (2014) 1.02
Rapid whole genome sequencing and precision neonatology. Semin Perinatol (2015) 0.99
From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol (2006) 0.98
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol (2014) 0.96
High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer (2015) 0.96
The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Mod Pathol (2013) 0.96
Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther (2013) 0.96
Pathology economic model tool: a novel approach to workflow and budget cost analysis in an anatomic pathology laboratory. Arch Pathol Lab Med (2010) 0.92
Intra-tumor genetic heterogeneity in rectal cancer. Lab Invest (2015) 0.92
Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors. Exp Mol Pathol (2015) 0.92
Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res (2011) 0.91
Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management. Curr Treat Options Oncol (2013) 0.91
Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care. Virchows Arch (2014) 0.91
Comparison of Accuracy of Whole-Exome Sequencing with Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tissue Samples. PLoS One (2015) 0.88
Molecular testing in oncology: problems, pitfalls and progress. Lung Cancer (2014) 0.88
Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice. Curr Pediatr Rev (2015) 0.87
Molecular diagnosis of soft tissue neoplasia: clinical applications and recent advances. Expert Rev Mol Diagn (2014) 0.87
The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. J Intern Med (2015) 0.87
Whole slide imaging: uses and limitations for surgical pathology and teaching. Biotech Histochem (2015) 0.86
Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy. Surgery (2015) 0.86
Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy. Cancer Genet (2013) 0.85
Clinical Impact and Cost-Effectiveness of Whole Exome Sequencing as a Diagnostic Tool: A Pediatric Center's Experience. Front Pediatr (2015) 0.85
Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations. J Mol Diagn (2015) 0.85
Personalized medicine in oncology: tailoring the right drug to the right patient. Biomark Med (2010) 0.85
Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol (2002) 0.84
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet (2015) 0.84
Translating genomic discoveries to the clinic in pediatric oncology. Curr Opin Pediatr (2015) 0.83
Role of targeted therapy in combination with surgery in renal cell carcinoma. Int J Urol (2015) 0.82
Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer. Chin J Cancer (2012) 0.82
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. BMC Cancer (2016) 0.82
Integrated analysis of numerous heterogeneous gene expression profiles for detecting robust disease-specific biomarkers and proposing drug targets. Nucleic Acids Res (2015) 0.81
A brief historical note on staining by hematoxylin and eosin. Am J Dermatopathol (1986) 0.81
The Therapeutic Target Database: an internet resource for the primary targets of approved, clinical trial and experimental drugs. Expert Opin Ther Targets (2011) 0.81
Comprehensive lipid profiling of plasma in patients with benign breast tumor and breast cancer reveals novel biomarkers. Anal Bioanal Chem (2015) 0.80
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol (2015) 0.79
Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. J Pers Med (2013) 0.79
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. PLoS One (2015) 0.79
Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis. Cancer Cytopathol (2016) 0.79
GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials. Cancer Inform (2015) 0.79
Proteomics in cancer research: Are we ready for clinical practice? Crit Rev Oncol Hematol (2015) 0.79
Lessons from the history of light microscopy. Nat Cell Biol (2000) 0.78
Single circulating tumor cell sequencing as an advanced tool in cancer management. Expert Rev Mol Diagn (2015) 0.78
Proteomics and drug discovery in cancer. Drug Discov Today (2015) 0.78
Not the End of the Odyssey: Parental Perceptions of Whole Exome Sequencing (WES) in Pediatric Undiagnosed Disorders. J Genet Couns (2016) 0.77
Cancer: Oncogenes in context. Nature (2010) 0.77
Pineal parenchymal tumor of intermediate differentiation with papillary features: a continuum of primary pineal tumors? J Neurooncol (2010) 0.76
mTORC1 activation in childhood ependymoma and response to sirolimus. J Neurooncol (2010) 0.76
Integrating next-generation sequencing into clinical cancer diagnostics. Expert Rev Mol Diagn (2013) 0.76
Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin. Mod Pathol (2016) 0.76
Translational Research and Plasma Proteomic in Cancer. J Cell Biochem (2015) 0.76
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. Am J Cancer Res (2014) 0.76